306 related articles for article (PubMed ID: 35177463)
1. Assessment of global coagulation function under treatment with emicizumab concomitantly with bypassing agents in haemophilia A with inhibitor (UNEBI Study): multicentre open-label non-randomised clinical trial.
Ogiwara K; Taki M; Suzuki T; Takedani H; Matsushita T; Amano K; Matsumoto M; Nishio K; Shima M; Kasahara M; Nogami K
BMJ Open; 2022 Feb; 12(2):e056922. PubMed ID: 35177463
[TBL] [Abstract][Full Text] [Related]
2. Study protocol for assessment of the coagulation potential of concomitantly used factor VIII concentrates in patients with haemophilia A with emicizumab prophylaxis (CAGUYAMA Study): a multicentre open-label non-randomised clinical trial.
Takeyama M; Ozu N; Kasama S; Kasahara M; Matsumoto M; Shima M; Nogami K
BMJ Open; 2023 Jul; 13(7):e072565. PubMed ID: 37429679
[TBL] [Abstract][Full Text] [Related]
3. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study.
Pipe SW; Shima M; Lehle M; Shapiro A; Chebon S; Fukutake K; Key NS; Portron A; Schmitt C; Podolak-Dawidziak M; Selak Bienz N; Hermans C; Campinha-Bacote A; Kiialainen A; Peerlinck K; Levy GG; Jiménez-Yuste V
Lancet Haematol; 2019 Jun; 6(6):e295-e305. PubMed ID: 31003963
[TBL] [Abstract][Full Text] [Related]
4. Prediction of the haemostatic effects of bypassing therapy using comprehensive coagulation assays in emicizumab prophylaxis-treated haemophilia A patients with inhibitors.
Furukawa S; Nogami K; Shimonishi N; Nakajima Y; Matsumoto T; Shima M
Br J Haematol; 2020 Sep; 190(5):727-735. PubMed ID: 32162680
[TBL] [Abstract][Full Text] [Related]
5. A modified thrombin generation assay to evaluate the plasma coagulation potential in the presence of emicizumab, the bispecific antibody to factors IXa/X.
Ogiwara K; Nogami K; Matsumoto N; Noguchi-Sasaki M; Hirata M; Soeda T; Shima M
Int J Hematol; 2020 Nov; 112(5):621-630. PubMed ID: 32748217
[TBL] [Abstract][Full Text] [Related]
6. Comparisons of global coagulation potential and bleeding episodes in emicizumab-treated hemophilia A patients and mild hemophilia A patients.
Nakajima Y; Mizumachi K; Shimonishi N; Furukawa S; Yada K; Ogiwara K; Takeyama M; Shima M; Nogami K
Int J Hematol; 2022 Apr; 115(4):489-498. PubMed ID: 35043383
[TBL] [Abstract][Full Text] [Related]
7. Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti-factor IXa/factor X bispecific antibody emicizumab.
Nogami K; Matsumoto T; Tabuchi Y; Soeda T; Arai N; Kitazawa T; Shima M
J Thromb Haemost; 2018 Jun; 16(6):1078-1088. PubMed ID: 29645406
[TBL] [Abstract][Full Text] [Related]
8. Management of people with haemophilia A undergoing surgery while receiving emicizumab prophylaxis: Real-world experience from a large comprehensive treatment centre in the US.
Lewandowska M; Randall N; Bakeer N; Maahs J; Sagar J; Greist A; Shapiro AD
Haemophilia; 2021 Jan; 27(1):90-99. PubMed ID: 33245841
[TBL] [Abstract][Full Text] [Related]
9. AOZORA: long-term safety and joint health in paediatric persons with haemophilia A without factor VIII inhibitors receiving emicizumab - protocol for a multicentre, open-label, phase IV clinical study.
Shima M; Takedani H; Kitsukawa K; Taki M; Ishiguro A; Nagao A; Yamaguchi-Suita H; Kyogoku Y; Yoshida S; Nogami K
BMJ Open; 2022 Jun; 12(6):e059667. PubMed ID: 35697445
[TBL] [Abstract][Full Text] [Related]
10. Emicizumab Prophylaxis in Hemophilia A with Inhibitors.
Oldenburg J; Mahlangu JN; Kim B; Schmitt C; Callaghan MU; Young G; Santagostino E; Kruse-Jarres R; Negrier C; Kessler C; Valente N; Asikanius E; Levy GG; Windyga J; Shima M
N Engl J Med; 2017 Aug; 377(9):809-818. PubMed ID: 28691557
[TBL] [Abstract][Full Text] [Related]
11. Bispecific Antibody Emicizumab for Haemophilia A: A Breakthrough for Patients with Inhibitors.
Mahlangu JN
BioDrugs; 2018 Dec; 32(6):561-570. PubMed ID: 30430367
[TBL] [Abstract][Full Text] [Related]
12. DosEmi study protocol: a phase IV, multicentre, open-label, crossover study to evaluate non-inferiority of pharmacokinetic-guided reduced dosing compared with conventional dosing of emicizumab in people with haemophilia A.
Donners A; van der Zwet K; Egberts ACG; Fijnvandraat K; Mathôt R; Kruis I; Cnossen MH; Schutgens R; Urbanus RT; Fischer K
BMJ Open; 2023 Jun; 13(6):e072363. PubMed ID: 37369395
[TBL] [Abstract][Full Text] [Related]
13. Emicizumab Improves Ex Vivo Clotting Function in Patients with Mild/Moderate Hemophilia A.
Nakajima Y; Nogami K; Yada K; Furukawa S; Noguchi-Sasaki M; Hirata M; Shima M
Thromb Haemost; 2020 Jun; 120(6):968-976. PubMed ID: 32384547
[TBL] [Abstract][Full Text] [Related]
14. Emergency management in patients with haemophilia A and inhibitors on prophylaxis with emicizumab: AICE practical guidance in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET.
Castaman G; Santoro C; Coppola A; Mancuso ME; Santoro RC; Bernardini S; Pugliese FR; Lubrano R; Golato M; Tripodi A; Rocino A; Santagostino E; ; Biasoli C; Borchiellini A; Catalano A; Contino L; Coluccia A; Cultrera D; De Cristofaro R; Di Minno G; Fabbri A; Franchini M; Gamba G; Giuffrida AC; Gresele P; Giampaolo A; Hassan HJ; Luciani M; Marchesini E; Marino R; Mazzucconi MG; Molinari AC; Morfini M; Notarangelo LD; Peccarisi L; Peyvandi F; Pollio B; Rivolta GF; Ruggieri MP; Sargentini V; Schiavoni M; Sciacovelli L; Serino ML; Siragusa S; Tagliaferri A; Testa S; Tosetto A; Zampogna S; Zanon E
Blood Transfus; 2020 Mar; 18(2):143-151. PubMed ID: 31657709
[TBL] [Abstract][Full Text] [Related]
15. Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving Emicizumab. Interim guidance from UKHCDO Inhibitor Working Party and Executive Committee.
Collins PW; Liesner R; Makris M; Talks K; Chowdary P; Chalmers E; Hall G; Riddell A; Percy CL; Hay CR; Hart DP
Haemophilia; 2018 May; 24(3):344-347. PubMed ID: 30070072
[TBL] [Abstract][Full Text] [Related]
16. Economic impact model of delayed inhibitor development in patients with hemophilia a receiving emicizumab for the prevention of bleeding events.
Patel AM; Corman SL; Chaplin S; Raimundo K; Sidonio RF
J Med Econ; 2019 Dec; 22(12):1328-1337. PubMed ID: 31530050
[No Abstract] [Full Text] [Related]
17. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors.
Young G; Liesner R; Chang T; Sidonio R; Oldenburg J; Jiménez-Yuste V; Mahlangu J; Kruse-Jarres R; Wang M; Uguen M; Doral MY; Wright LY; Schmitt C; Levy GG; Shima M; Mancuso ME
Blood; 2019 Dec; 134(24):2127-2138. PubMed ID: 31697801
[TBL] [Abstract][Full Text] [Related]
18. AKATSUKI study: a prospective, multicentre, phase IV study evaluating the safety of emicizumab under and immediately after immune tolerance induction therapy in persons with congenital haemophilia A with factor VIII inhibitors.
Matsushita T; Suzuki N; Nagao A; Nagae C; Yamaguchi-Suita H; Kyogoku Y; Ioka A; Nogami K
BMJ Open; 2022 Mar; 12(3):e057018. PubMed ID: 35288393
[TBL] [Abstract][Full Text] [Related]
19. The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study.
Oldenburg J; Mahlangu JN; Bujan W; Trask P; Callaghan MU; Young G; Asikanius E; Peyvandi F; Santagostino E; Kruse-Jarres R; Negrier C; Kessler C; Xu J; Windyga J; Shima M; von Mackensen S
Haemophilia; 2019 Jan; 25(1):33-44. PubMed ID: 30427582
[TBL] [Abstract][Full Text] [Related]
20. Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A.
Shima M; Hanabusa H; Taki M; Matsushita T; Sato T; Fukutake K; Fukazawa N; Yoneyama K; Yoshida H; Nogami K
N Engl J Med; 2016 May; 374(21):2044-53. PubMed ID: 27223146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
